Kilitch Drugs

KILITCH02 May 2024

Pharmaceuticals

₹

-5.85 (-1.61%)

Lowest Today

Highest Today

Prev. Close

Today’s Open

52 Week High

52 Week Low

BUY

SELL

To Invest in Kilitch Drugs

Kilitch Drugs

Pharmaceuticals

KILITCH02 May 2024

₹

-5.85 (-1.61%)

OverviewFundamentals

Corporate action

Peer comparison

Income Sheet

Balance sheet

Cash flow

Share holding

About Us

Corporate Action

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

All

Dividends

Bonus

Splits

Others

Ex-Date	Type	Description	Record Date
30-May-2019	D	Kilitch Drugs India Ltd has informed BSE that the Board of Directors of the Company at its Meeting held on May 30, 2019, inter alia, have recommended a final dividend of Re. 0.50/- per equity share (face value of Rs. 10/- each) for the financial year 2018-19, subject to the approval of the Members at the ensuing Annual General Meeting ('AGM') of the Company. The dividend, if approved by the Members shall be paid within 30 days from the date of AGM.	20-Sep-2019
25-May-2018	D	Kilitch Drugs India Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 25, 2018, in alia , has recommended a final dividend of Re. 0.50 per Equity Share ( Face Value of Re. 10/- each) for the year ended 31st March, 2018. This dividend upon approval by the shareholders at the ensuing Annual General Meeting (AGM) will be paid within 30 days from the date of AGM.	18-Sep-2018
30-Aug-2012	D	Kilitch Drugs India Ltd has informed BSE that the Board of Directors of the Company at its meeting held on August 30, 2012, inter alia, 1. Declared Special Interim dividend @ 300% (i.e. Rs.30/- per equity share of Rs.10/- each) on the equity shares of the Company.	24-Sep-2012
25-Jul-2011	D	Kilitch Drugs India Ltd has informed BSE that the Board of Directors of the Company at its meeting held on July 25, 2011, inter alia, has: 1. Recommended dividend @ 10% [i.e. Re. 1/- per equity share of Rs. 10/- each] on the equity shares of the Company, subject to the approval of the Members at the ensuing 19th Annual General Meeting;	18-Aug-2011
16-Sep-2010	D	Kilitch Drugs India Ltd has now informed BSE that the Board of Directors at their meeting held on August 10, 2010 had recommended the dividend of Rs. 1/- (10%) on Rs. 10/- per share on 13202122 equity shares of Rs. 10/- each aggregating to Rs. 13202122/- subject to the approval of the members at the forthcoming 18th Annual General Meeting which is scheduled to be held on September 20, 2010.	14-Oct-2010
03-Jul-2009	D	Kilitch Drugs India Ltd has informed BSE that the Board of Directors of the Company at its meeting held on June 30, 2009, inter alia, has recommended dividend @ 10% for the financial year 2008-09 subject to approval of the members at the ensuing Annual General Meeting of the Company.	10-Sep-2009
23-Jun-2008	D	Kilitch Drugs India Ltd has informed BSE that the Board of Directors of the Company at its meeting held on June 21, 2008, inter alia, has recommended a Final Dividend of 10% on the Equity Share Capital, subject to approval by Shareholders. Thus, if approved, the total dividend, inclusive of the interim dividend, for the year would aggregate to 20%.	10-Sep-2008
02-Nov-2007	D	Kilitch Drugs India Ltd has informed BSE that the Board of Directors of the Company at its meeting held on October 31, 2007, inter alia, has declared Interim Dividend @ 10% per share of the Company.	15-Nov-2007
31-Jan-2024	BC	KILITCH DRUGS (INDIA) LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/02/2024 inter alia to consider and approve the unaudited standalone and consoli	08-Feb-2024
11-Aug-2023	BC	Considered and approved financial results for the quarter ended 30th June, 2023	14-Nov-2023
01-Nov-2023	BC	KILITCH DRUGS (INDIA) LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/11/2023 inter alia to consider and approve and consider the unaudited Financial	09-Nov-2023
11-Aug-2023	BC	Considered and approved financial results for the quarter ended 30th June, 2023 Detail disclosure of Book Closure for the purpose of AGM is hereby enclosed Intimation to Stock Exchanges regardi	29-Sep-2023
14-Aug-2023	BC	Annual General Meeting	22-Sep-2023

Announcement Date30-May-2019

Ex Dividend Date20-Sep-2019

Dividend(%)5

Announcement Date25-May-2018

Ex Dividend Date18-Sep-2018

Dividend(%)5

Announcement Date30-Aug-2012

Ex Dividend Date24-Sep-2012

Dividend(%)300

Announcement Date25-Jul-2011

Ex Dividend Date18-Aug-2011

Dividend(%)10

Announcement Date16-Sep-2010

Ex Dividend Date14-Oct-2010

Dividend(%)10

Announcement Date03-Jul-2009

Ex Dividend Date10-Sep-2009

Dividend(%)10

Announcement Date23-Jun-2008

Ex Dividend Date10-Sep-2008

Dividend(%)10

Announcement Date02-Nov-2007

Ex Dividend Date15-Nov-2007

Dividend(%)10

No Rights has been declared by KILITCH

Book Closure

Record Date	Split Date	Purpose
08-Feb-2024	-	KILITCH DRUGS (INDIA) LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/02/2024 inter alia to consider and approve the unaudited standalone and consoli
14-Nov-2023	-	Considered and approved financial results for the quarter ended 30th June, 2023
09-Nov-2023	-	KILITCH DRUGS (INDIA) LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/11/2023 inter alia to consider and approve and consider the unaudited Financial
29-Sep-2023	-	Considered and approved financial results for the quarter ended 30th June, 2023 Detail disclosure of Book Closure for the purpose of AGM is hereby enclosed Intimation to Stock Exchanges regardi
22-Sep-2023	01 Jan'1900	Annual General Meeting

Peer Comparison

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

Scrip Name	Price	Daily Change	M.Cap (Cr)	1 Year Returns %	P/E (TTM)	PB Ratio
Kilitch Drugs (India) Ltd ₹356.85(-5.85/-1.61%)	356.85	-5.85	573.90	100.59	30.01	2.70
Lupin Ltd ₹1,647.65(+1.75/0.11%)	1,647.65	+1.75	75,091.67	132.46	36.44	3.90
Ipca Laboratories Ltd ₹1,351.00(+11.50/0.86%)	1,351.00	+11.50	34,275.44	90.72	62.23	5.52
J B Chemicals & Pharmaceuticals Ltd ₹1,885.60(-19.65/-1.03%)	1,885.60	-19.65	29,263.53	81.31	57.83	10.91
Sanofi India Ltd ₹8,677.75(+352.20/4.23%)	8,677.75	+352.20	19,984.86	59.90	33.85	19.68
IOL Chemicals & Pharmaceuticals Ltd ₹392.30(-1.40/-0.36%)	392.30	-1.40	2,303.02	-4.21	13.36	1.45

Income Sheet

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

Standalone

Consolidated

Column	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22
Gross Sales	29.77	31.57	31.12	43.28	28.50	22.43
Excise Duty	0.00	0.00	0.00	0.00	0.00	0.00
Net Sales	29.77	31.57	31.12	43.28	28.50	22.43
Other Operating Income	0.00	0.00	0.00	0.00	0.00	0.00
Other Income	3.40	0.92	0.98	1.43	1.11	0.66
Total Income	33.16	32.49	32.10	44.71	29.62	23.09
Total Expenditure	25.75	25.73	25.89	36.60	24.29	19.29
PBIDT	7.41	6.76	6.22	8.12	5.33	3.80
Interest	0.53	0.55	0.38	0.41	0.28	0.23
PBDT	6.88	6.21	5.84	7.71	5.05	3.58
Depreciation	0.30	0.28	0.26	0.37	0.38	0.31
Tax	1.30	1.76	1.99	2.04	1.45	-0.57
Deferred Tax	-0.22	-0.07	-0.59	0.17	-0.70	0.18
Reported Profit After Tax	5.50	4.24	4.19	5.13	3.93	3.64
Extra-ordinary Items	0.00	0.00	0.00	0.00	0.00	0.00
Adjusted Profit After Extra-ordinary item	5.50	4.24	4.19	5.13	3.93	3.64

EPS (Unit Curr.)	3.48	2.60	2.69	3.29	2.53	2.34
EPS (Adj) (Unit Curr.)	3.48	2.60	2.69	3.29	2.53	2.34
Calculated EPS (Unit Curr.)	3.42	2.64	2.69	3.29	2.52	2.34
Calculated EPS (Adj) (Unit Curr.)	3.42	2.64	2.69	3.29	2.52	2.34
Calculated EPS (Ann.) (Unit Curr.)	13.68	10.55	10.75	13.16	10.09	9.36
Calculated EPS (Adj) (Ann.) (Unit Curr.)	13.68	10.55	10.75	13.16	10.09	9.36
Book Value (Unit Curr.)	0.00	0.00	0.00	0.00	0.00	0.00
Dividend (%)	0.00	0.00	0.00	0.00	0.00	0.00
Equity	16.08	16.08	15.58	15.58	15.58	15.58
Reserve & Surplus	0.00	0.00	0.00	0.00	0.00	0.00
Face Value	10.00	10.00	10.00	10.00	10.00	10.00

Public Shareholding (No. Of Shares)	0.00	0.00	0.00	0.00	0.00	0.00
Public Shareholding (% in Equity)	0.00	0.00	0.00	0.00	0.00	0.00

Pledged/Encumbered - No. of Shares	0.00	0.00	0.00	0.00	0.00	0.00
Pledged/Encumbered - % in Total Promoters Holding	0.00	0.00	0.00	0.00	0.00	0.00
Pledged/Encumbered - % in Total Equity	0.00	0.00	0.00	0.00	0.00	0.00

Non Encumbered - No. of Shares	0.00	0.00	0.00	0.00	0.00	0.00
Non Encumbered - % in Total Promoters Holding	0.00	0.00	0.00	0.00	0.00	0.00
Non Encumbered - % in Total Equity	0.00	0.00	0.00	0.00	0.00	0.00

PBIDTM(%)	24.89	21.41	19.99	18.76	18.70	16.94
PBDTM(%)	23.11	19.67	18.77	17.81	17.72	15.96
PATM(%)	18.47	13.43	13.46	11.85	13.79	16.23

Column	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22
Gross Sales	31.79	41.20	36.56	45.48	29.97	30.70
Excise Duty	0.00	0.00	0.00	0.00	0.00	0.00
Net Sales	31.79	41.20	36.56	45.48	29.97	30.70
Other Operating Income	0.00	0.00	0.00	0.00	0.00	0.00
Other Income	2.96	0.49	0.56	1.02	0.69	0.24
Total Income	34.75	41.69	37.12	46.50	30.66	30.94
Total Expenditure	29.51	32.58	30.38	39.26	25.99	26.74
PBIDT	5.24	9.11	6.74	7.23	4.67	4.19
Interest	1.60	1.51	1.50	1.21	1.29	1.75
PBDT	3.64	7.60	5.24	6.03	3.38	2.44
Depreciation	0.81	0.82	0.71	0.91	0.93	0.89
Minority Interest Before NP	0.00	0.00	0.00	0.00	0.00	0.00
Tax	1.30	1.76	2.07	2.04	1.45	-0.57
Deferred Tax	-0.22	-0.07	-0.59	0.17	-0.70	0.18
Reported Profit After Tax	1.74	5.09	3.06	2.90	1.71	1.94
Minority Interest After NP	-1.17	0.35	-0.30	-0.66	-0.66	-0.49
Net Profit after Minority Interest	2.91	4.74	3.36	3.56	2.37	2.43

Extra-ordinary Items	0.00	0.00	0.00	0.00	0.00	0.00
Adjusted Profit After Extra-ordinary item	2.91	4.74	3.36	3.56	2.37	2.43

EPS (Unit Curr.)	1.85	2.93	2.15	2.29	1.52	1.56
Book Value (Unit Curr.)	0.00	0.00	0.00	0.00	0.00	0.00
Dividend (%)	0.00	0.00	0.00	0.00	0.00	0.00
Equity	16.08	16.08	15.58	15.58	15.58	15.58

Public Shareholding (Number)	0.00	0.00	0.00	0.00	0.00	0.00
Public Shareholding (%)	0.00	0.00	0.00	0.00	0.00	0.00

Pledged/Encumbered - No. of Shares	0.00	0.00	0.00	0.00	0.00	0.00
Pledged/Encumbered - % in Total Promoters Holding	0.00	0.00	0.00	0.00	0.00	0.00
Pledged/Encumbered - % in Total Equity	0.00	0.00	0.00	0.00	0.00	0.00

Non Encumbered - No. of Shares	0.00	0.00	0.00	0.00	0.00	0.00
Non Encumbered - % in Total Promoters Holding	0.00	0.00	0.00	0.00	0.00	0.00
Non Encumbered - % in Total Equity	0.00	0.00	0.00	0.00	0.00	0.00

PBIDTM(%)	16.48	22.11	18.44	15.90	15.58	13.65
PBDTM(%)	11.45	18.45	14.33	13.26	11.28	7.95
PATM(%)	5.47	12.35	8.37	6.38	5.71	6.32

Balance Sheet

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

Standalone

Consolidated

Column	Mar 23	Mar 22	Mar 21	Mar 20	Mar 19	Mar 18
SOURCES OF FUNDS :
Share Capital	15.58	15.58	15.49	15.43	15.36	13.73
Reserves Total	175.35	162.45	147.44	136.21	135.73	115.10
Equity Share Warrants	5.00	0.00	0.00	0.00	0.00	2.36
Equity Application Money	0.00	0.00	0.00	0.00	0.00	0.00
Total Shareholders Funds	195.93	178.03	162.93	151.64	151.09	131.19
Secured Loans	21.86	20.33	14.71	12.51	9.36	0.82
Unsecured Loans	0.00	0.00	0.00	0.00	0.00	0.00
Total Debt	21.86	20.33	14.71	12.51	9.36	0.82
Total Liabilities	217.79	198.36	177.64	164.15	160.45	132.01
APPLICATION OF FUNDS :
Gross Block	38.16	35.93	27.74	27.31	26.31	24.64
Less : Accumulated Depreciation	23.08	21.75	20.79	19.64	18.49	17.29
Less:Impairment of Assets	0.00	0.00	0.00	0.00	0.00	0.00
Net Block	15.08	14.18	6.95	7.67	7.82	7.35
Lease Adjustment	0.00	0.00	0.00	0.00	0.00	0.00
Capital Work in Progress	1.31	0.00	0.00	0.00	0.00	0.00
Producing Properties	0.00	0.00	0.00	0.00	0.00	0.00
Investments	110.29	117.38	106.50	98.08	99.65	100.54
Current Assets, Loans & Advances	0.00	0.00	0.00	0.00	0.00	0.00
Inventories	2.04	5.00	3.59	5.56	4.72	2.80
Sundry Debtors	53.10	41.42	22.92	17.01	23.15	20.72
Cash and Bank	17.97	2.45	5.77	2.72	4.07	3.87
Loans and Advances	2.46	1.61	3.09	2.92	3.87	4.15
Total Current Assets	75.57	50.48	35.37	28.21	35.80	31.54
Less : Current Liabilities and Provisions	0.00	0.00	0.00	0.00	0.00	0.00
Current Liabilities	29.00	28.25	14.40	8.53	8.77	10.57
Provisions	5.55	5.41	3.43	1.04	2.40	2.78
Total Current Liabilities	34.55	33.65	17.83	9.57	11.17	13.34
Net Current Assets	41.02	16.83	17.54	18.64	24.63	18.20
Miscellaneous Expenses not written off	0.00	0.00	0.00	0.00	0.00	0.00
Deferred Tax Assets	1.97	1.51	1.27	0.96	1.03	1.55
Deferred Tax Liability	0.00	0.00	0.00	0.00	0.00	0.00
Net Deferred Tax	1.97	1.51	1.27	0.96	1.03	1.55
Total Assets	169.67	149.90	132.25	125.35	133.13	127.64
Contingent Liabilities	0.76	0.76	0.76	5.80	5.80	5.72

Column	Mar 23	Mar 22	Mar 21	Mar 20	Mar 19	Mar 18
SOURCES OF FUNDS :
Share Capital	15.58	15.58	15.49	15.43	15.36	13.73
Reserves Total	131.01	121.00	111.63	102.82	105.70	98.30
Equity Share Warrants	5.00	2.50	0.00	0.00	0.00	0.00
Equity Application Money	0.00	0.00	0.00	0.00	0.00	0.00
Total Shareholders Funds	151.59	139.08	127.12	118.25	121.06	112.03
Minority Interest	-1.02	1.21	2.35	2.22	2.10	0.73
Secured Loans	21.86	20.33	14.71	12.51	9.36	0.82
Unsecured Loans	0.33	0.10	0.10	0.10	0.10	0.10
Total Debt	22.19	20.43	14.81	12.61	9.46	0.92
Policy Holders Fund	0.00	0.00	0.00	0.00	0.00	0.00
Other Liabilities	0.07	0.28	0.38	0.39	0.41	0.00
Total Liabilities	172.83	161.00	144.66	133.47	133.03	113.68
APPLICATION OF FUNDS :
Gross Block	111.28	108.05	71.01	70.59	69.19	68.00
Less: Accumulated Depreciation	47.06	43.51	41.05	39.06	37.06	35.03
Less: Impairment of Assets	0.00	0.00	0.00	0.00	0.00	0.00
Net Block	64.22	64.54	29.96	31.53	32.13	32.97
Lease Adjustment	0.00	0.00	0.00	0.00	0.00	0.00
Capital Work in Progress	3.62	3.16	65.48	29.60	20.25	3.18
Producing Properties	0.00	0.00	0.00	0.00	0.00	0.00
Investments	61.86	71.17	60.28	51.86	53.44	56.29
Current Assets, Loans & Advances	0.00	0.00	0.00	0.00	0.00	0.00
Inventories	2.04	5.00	3.59	5.56	4.72	2.80
Sundry Debtors	54.29	41.41	22.92	15.86	19.44	20.69
Cash and Bank	19.98	10.06	12.50	2.80	7.94	4.77
Loans and Advances	10.89	10.40	4.96	3.76	4.37	4.43
Total Current Assets	87.20	66.87	43.96	27.97	36.46	32.69
Less : Current Liabilities and Provisions	0.00	0.00	0.00	0.00	0.00	0.00
Current Liabilities	41.12	43.44	55.06	8.32	8.24	11.21
Provisions	5.56	5.41	3.45	1.04	2.40	2.78
Total Current Liabilities	46.68	48.85	58.51	9.36	10.64	13.99
Net Current Assets	40.52	18.02	-14.55	18.61	25.82	18.70
Miscellaneous Expenses not written off	0.00	0.00	0.00	0.00	0.00	0.00
Deferred Tax Assets	1.98	1.51	1.28	0.97	1.04	1.55
Deferred Tax Liability	0.00	0.00	0.00	0.00	0.00	0.00
Net Deferred Tax	1.98	1.51	1.28	0.97	1.04	1.55
Other Assets	0.64	2.60	2.20	0.90	0.34	1.01
Total Assets
Contingent Liabilities	0.76	0.76	5.80	5.80	5.80	0.00

Cash Flow

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

PARTICULARS	Mar 2023	Mar 2022	Mar 2021	Mar 2020	Mar 2019
Cash and Cash Equivalents at Beginning of the year	2.45	5.77	2.72	4.07	3.87
Net Cash from Operating Activities	6.10	5.21	6.13	7.29	7.42
Net Cash Used In Investing Activities	6.24	-16.08	-5.35	-10.08	-21.90
Net Cash Used In Financing Activities	3.04	7.55	2.27	1.44	14.69
Net Inc./Dec In Cash And Cash Equivalents	15.39	-3.32	3.05	-1.35	0.20
Cash And Cash Equivalents At End Of The Year	17.84	2.45	5.77	2.72	4.07

Share Holding

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

Promoter Shareholding

69.23%

FII Shareholding

0.00%

DII Shareholding

0.00%

Public Shareholding

30.77%

**Promoter pledged shareholding 69.23%

About Kilitch Drugs (India) Ltd

Kilitch Drugs (India) Ltd is in the Pharmaceuticals sector, having a market capitalization of Rs. 571.97 crores. It has reported a sales of Rs. 29.77 crores and a net profit of Rs. 5.5 crores for the quarter ended December 2018. The company management includes Mukund P Mehta, Mukund P Mehta,Bhavin M Mehta,Hemang Engineer,Mira Bhavin Mehta,Murti Vasudev Krishna,Venkita Subramanian Rajan,Pushpa Nyoupane (Kilitch Drugs (India) Ltd) among others.

Chairman

Mukund P Mehta

Registered office

C-301/2 MIDC TTC Indl Area,Pawane Village,Thane,Maharashtra,400705

FAX :91-022-27680912

Background

Incorporation Year1992

Face Value₹10

Market Lot1

How to buy Kilitch Drugs shares on nse?

To buy Kilitch Drugs shares in Motilal Oswal, you just need to open a demat account and get your KYC documents verified

What is the Kilitch Drugs share price today?

The Kilitch Drugs shares price on nse is Rs.356.85 today.

What is the market cap of Kilitch Drugs shares on NSE ?

The company has a market capitalization of Rs.573.90Cr

What is the PE & PB ratio of Kilitch Drugs shares ?

PE is 30.01 and PB is 2.7

What is the 52 Week High and Low of Kilitch Drugs shares?

Kilitch Drugs stock price high: Rs.470 Kilitch Drugs stock price low: Rs.175